$HIMS (+4.16%) Shares of telehealth company Hims & Hers fall 9% in premarket trading to $37.2 ** A U.S. federal judge (link) has denied a preliminary injunction that would have allowed compounding pharmacies to continue making copies of Eli Lilly's popular weight-loss drug Zepbound in the U.S. ** The Outsourcing Facilities Association filed a lawsuit against the FDA in Oct, because it had removed the drug from the drug shortage list and it remains in short supply ** HIMS sells compounded versions of Novo Nordisk's Wegovy and Ozempic, chemically known as semaglutide ** The ruling has "direct bearing on the pending semaglutide case, which we also expect to go in the FDA's favor," according to brokerage Citi ** HIMS shares have nearly tripled in the last 12 months
Source: Reuters.com
